drugset / Trial / NCT04030533
Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants
Non-randomizedSequentialOpen-labelOther
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of guselkumab following a single intravenous (IV) or subcutaneous (SC) administration in healthy Chinese participants; to evaluate the PK of ustekinumab following a single IV administration in healthy participants.
Timeline
- Start
- 2019-11-29
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Ustekinumab | Monoclonal antibody | 6 mg/ml | Intravenous |
Indications
No indication recorded.